Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.

Takeshi MochizukiKatsunori IkariKoichiro YanoMotoaki SatoKen Okazaki

Published in: Modern rheumatology (2018)

MTX in patients with RA treated with abatacept was a risk factor for deterioration of ILD. Discontinuation of MTX should be considered one of treatment reduction to prevent the deterioration of ILD.

Keyphrases

interstitial lung disease
rheumatoid arthritis
systemic sclerosis
disease activity
idiopathic pulmonary fibrosis
ankylosing spondylitis
rheumatoid arthritis patients
newly diagnosed
systemic lupus erythematosus
smoking cessation